Abbott Laboratories (Pakistan) Limited
City Office:
11th & 12th Floors, Ocean Tower, G-3,
Block-9, Main Clifton Road,
Karachi, Sindh 75600
P.O. Box No. 13841, Karachi
Tel: +92-21-38709369, +92-21-32799018

Abbott Laboratories (Pakistan) Limited
Registered Office:
Opp. Radio Pakistan Transmission Centre,
Hyderabad Road, Landhi, Karachi-75120
P.O. Box 7229 Karachi 74400
Tel: +92-21-111-Abbott (111-222-688)

August 27th, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Sub: Financial Results for the Half Year Ended June 30th 2026

Dear Sir,

We have to inform you that the Board of Directors of our company in their meeting held on Thursday, August 27th, 2026 at 03:30 p.m.at the City Office, Abbott Laboratories (Pakistan) Limited, Karachi, recommended the following;

	Six Months Ended		Three Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	(Rupees in ' 000)			
Sales - net				
Local	37,150,866	34,913,845	19,977,939	18,057,357
Export	875,685	1,493,944	343,890	1,003,981
	38,026,551	36,407,789	20,321,829	19,061,338
Cost of sales	(23,576,445)	(23,792,889)	(12,569,531)	(12,288,344)
Gross Profit	14,450,106	12,614,900	7,752,298	6,772,994
Selling and distribution expenses	(6,145,400)	(5,527,267)	(3,227,285)	(2,805,964)
Administrative expenses	(776,092)	(638,195)	(395,770)	(335,172)
Other charges	(887,408)	(826,334)	(567,280)	(504,514)
Other income	593,980	416,745	364,514	156,646
	(7,214,920)	(6,575,051)	(3,825,821)	(3,489,004)
	7,235,186	6,039,849	3,926,477	3,283,990
Finance costs	(35,643)	(37,704)	(17,490)	(33,757)
Profit before minimum tax diffrential and income tax	7,199,543	6,002,145	3,908,987	3,250,233
Minimum tax differential	(159,446)	-	(159,446)	-
Profit before income tax	7,040,097	6,002,145	3,749,541	3,250,233
Income tax				
Current	(3,075,855)	(2,647,573)	(1,618,953)	(1,416,360)
Deferred	175,989	188,600	69,335	109,626
	(2,899,866)	(2,458,973)	(1,549,618)	(1,306,734)
Profit for the period	4,140,231	3,543,172	2,199,923	1,943,499
Earnings per share - basic and diluted	42.29	36.19	22.47	19.85

Abbott
life.to the fullest.

The Quarterly Report of the Company for the period ended June 30, 2026 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED

ABBOTT LABORATORIES (PAKISTAN) LTD. KARACHI

SYED ANIS AHMED
CHIEF EXECUTIVE &
MANAGING DIRECTOR

CC: To	CC: To
FAMCO Share Registration Services (Pvt) Ltd. 8-F, Next to Hotel Faran, Nursery, Block 6, PECHS, Shahrah-e-Faisal Karachi	Additionl Joint Registrar of Cmpanies Securities Exchange and Commission of Pakistan Company Registration Office Dawood Center, MT Khan Road, Cicil Lines Karachi

ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS
FOR THE SIX MONTHS AND THREE MONTHS ENDED JUNE 30, 2026
(UN-AUDITED)

	Note	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025
		---- Rupees in '000 ----			
Sales - net					
Local		**37,150,866**	34,913,845	**19,977,939**	18,057,357
Export		**875,685**	1,493,944	**343,890**	1,003,981
		38,026,551	36,407,789	**20,321,829**	19,061,338
Cost of sales		**(23,576,445)**	(23,792,889)	**(12,569,531)**	(12,288,344)
Gross Profit		**14,450,106**	12,614,900	**7,752,298**	6,772,994
Selling and distribution expenses		**(6,145,400)**	(5,527,267)	**(3,227,285)**	(2,805,964)
Administrative expenses		**(776,092)**	(638,195)	**(395,770)**	(335,172)
Other charges	16	**(887,408)**	(826,334)	**(567,280)**	(504,514)
Other income	17	**593,980**	416,745	**364,514**	156,646
		(7,214,920)	(6,575,051)	**(3,825,821)**	(3,489,004)
		7,235,186	6,039,849	**3,926,477**	3,283,990
Finance costs		**(35,643)**	(37,704)	**(17,490)**	(33,757)
Profit before minimum tax differential and income tax		**7,199,543**	6,002,145	**3,908,987**	3,250,233
Minimum tax differential		**(159,446)**	-	**(159,446)**	-
Profit before income tax		**7,040,097**	6,002,145	**3,749,541**	3,250,233
Income tax					
Current		**(3,075,855)**	(2,647,573)	**(1,618,953)**	(1,416,360)
Deferred		**175,989**	188,600	**69,335**	109,626
		(2,899,866)	(2,458,973)	**(1,549,618)**	(1,306,734)
Profit for the period		**4,140,231**	3,543,172	**2,199,923**	1,943,499
		---- Rupees ----			
Earnings per share - basic and diluted		**42.29**	36.19	**22.47**	19.85

The annexed notes 1 to 23 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE OFFICER	DIRECTOR	CHIEF FINANCIAL OFFICER

ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2026

	Note	June 30, 2026	December 31, 2025
		------- Rupees in '000 -------	
		(Un-audited)	(Audited)
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	7	15,745,230	15,635,851
Intangible assets		725	831
Long-term loans and advances		147,005	141,175
Long-term deposits		32,713	32,628
Long-term prepayments		13,874	12,395
Total non-current assets		15,939,547	15,822,880
CURRENT ASSETS			
Stores and spares		674,222	669,690
Stock-in-trade	8	16,282,823	12,447,838
Trade debts		2,860,381	2,820,530
Loans and advances	9	1,601,745	399,086
Trade deposits and short-term prepayments		457,093	313,552
Other receivables	10	1,249,562	1,005,069
Taxation - net		256,573	-
Cash and cash equivalents	11	9,436,049	13,337,551
Total current assets		32,818,448	30,993,316
TOTAL ASSETS		48,757,995	46,816,196
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Authorised capital			
200,000,000 (December 31, 2025: 200,000,000) Ordinary shares of Rs.10 /- each		2,000,000	2,000,000
Issued, subscribed and paid-up capital			
97,900,302 (December 31, 2025: 97,900,302) Ordinary shares of Rs. 10 /- each	12	979,003	979,003
Reserves			
Capital		2,320,886	2,073,901
Revenue		28,796,772	28,572,553
Total equity		32,096,661	31,625,457
NON-CURRENT LIABILITIES			
Deferred taxation - net		813,976	989,965
Staff retirement benefits		460,412	494,943
Lease liabilities	13	349,547	386,633
Total non-current liabilities		1,623,935	1,871,541
CURRENT LIABILITIES			
Trade and other payables	14	14,095,114	12,198,722
Unclaimed dividends		123,831	71,155
Taxation - net		-	246,958
Current maturity of lease liabilities	13	99,920	101,345
Provisions		718,534	701,018
Total current liabilities		15,037,399	13,319,198
CONTINGENCIES AND COMMITMENTS	15		
TOTAL EQUITY AND LIABILITIES		48,757,995	46,816,196

The annexed notes 1 to 23 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE OFFICER	DIRECTOR	CHIEF FINANCIAL OFFICER

ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE SIX MONTHS ENDED JUNE 30, 2026

	Issued, subscribed and paid-up capital	Reserves					Total equity
		Capital reserves		Revenue reserves			
		Reserve arising on merger	Share based compensation reserve	General reserve	Un-appropriated profit	Total	
	----- Rupees in '000 -----						
Balance as at January 1, 2025 (Audited)	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Final dividend for the year ended December 31, 2024 @ Rs 10.0 per share					(979,003)	(979,003)	(979,003)
Employee benefit cost under IFRS 2 - 'Share based payments'	-	-	147,275	-	-	147,275	147,275
Total comprehensive income for the period ended June 30, 2025							
Profit for the period	-	-	-	-	3,543,172	3,543,172	3,543,172
Other comprehensive income for the period - net of tax	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	3,543,172	3,543,172	3,543,172
Balance as at June 30, 2025 (Un-audited)	979,003	46,097	1,851,659	5,338,422	18,220,899	25,457,077	26,436,080
Balance as at January 01, 2026 (Audited)	**979,003**	**46,097**	**2,027,804**	**5,338,422**	**23,234,131**	**30,646,454**	**31,625,457**
Final dividend for the year ended December 31, 2025 @ Rs. 40/- per share	-	-	-	-	(3,916,012)	(3,916,012)	(3,916,012)
Employee benefit cost under IFRS 2 - 'Share based payments'	-	-	246,985	-	-	246,985	246,985
Total comprehensive income for the period ended June 30, 2026							
Profit for the period	-	-	-	-	4,140,231	4,140,231	4,140,231
Other comprehensive income for the period - net of tax	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	4,140,231	4,140,231	4,140,231
Balance as at June 30, 2026 (Un-audited)	979,003	46,097	2,274,789	5,338,422	23,458,350	31,117,658	32,096,661

The annexed notes 1 to 23 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE OFFICER | **DIRECTOR** | **CHIEF FINANCIAL OFFICER**

ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2026
(UN-AUDITED)

	Note	June 30, 2026	June 30, 2025
		---- Rupees in '000 ----	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	18	**4,577,438**	5,442,215
Income tax paid		**(3,579,375)**	(2,270,154)
Minimum tax differential paid		**(159,446)**	-
Long-term loans and advances - net		**(5,830)**	(9,835)
Long-term deposits - net		**(85)**	(25,200)
Long-term prepayments - net		**(1,479)**	2,629
Contributions to staff retirement benefit funds		**(186,359)**	(166,366)
Net movement in provisions		**17,516**	29,271
Net cash generated from operating activities		**662,380**	3,002,560
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to property, plant and equipment		**(1,108,368)**	(1,558,597)
Sale proceeds from disposal of operating fixed assets		**38,755**	150,585
Interest income		**443,220**	201,732
Net cash used in investing activities		**(626,393)**	(1,206,280)
CASH FLOWS FROM FINANCING ACTIVITIES			
Bank charges paid		**(4,011)**	(5,073)
Interest portion of lease liabilities paid		**(27,951)**	(18,105)
Principal portion of lease liabilities paid		**(42,191)**	(20,461)
Dividends paid		**(3,863,336)**	(760,544)
Net cash used in financing activities		**(3,937,489)**	(804,183)
Net (decrease) / increase in cash and cash equivalents		**(3,901,502)**	992,097
Cash and cash equivalents at the beginning of the period		**13,337,551**	6,182,349
Cash and cash equivalents at the end of the period		**9,436,049**	7,174,446

The annexed notes 1 to 23 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE OFFICER

DIRECTOR

CHIEF FINANCIAL OFFICER